600196 复星医药
已收盘 12-26 15:00:00
资讯
新帖
简况
复星医药：募投项目结项
南方财经网 · 12-24
复星医药：募投项目结项
复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块
证券日报 · 12-23
复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块
复星医药：控股子公司药品获美国FDA临床试验批准
南方财经网 · 12-19
复星医药：控股子公司药品获美国FDA临床试验批准
官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”
市场资讯 · 12-18
官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”
复星医药旗下公司与Clavis Bio签署共同开发及独家许可协议
美股速递 · 12-18
复星医药旗下公司与Clavis Bio签署共同开发及独家许可协议
复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议
智通财经 · 12-18
复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议
12月17日复星医药现784.3万元大宗交易
证券之星 · 12-17
12月17日复星医药现784.3万元大宗交易
甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究
新京报 · 12-16
甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究
复星医药收购绿谷医药，阿尔兹海默病患者看到曙光？
读懂财经 · 12-16
复星医药收购绿谷医药，阿尔兹海默病患者看到曙光？
复星医药14亿入局阿尔茨海默病 缘何选择押注绿谷“九期一”？
21世纪经济报道 · 12-15
复星医药14亿入局阿尔茨海默病 缘何选择押注绿谷“九期一”？
争议药物"九期一"获新生？复星医药14亿元收购绿谷医药重启临床与商业化
蓝鲸财经 · 12-15
争议药物"九期一"获新生？复星医药14亿元收购绿谷医药重启临床与商业化
复星医药：控股子公司拟出资14.12亿元投资绿谷医药
每日经济新闻 · 12-15
复星医药：控股子公司拟出资14.12亿元投资绿谷医药
复星医药称子公司计划投资总额14亿元以收购制药公司控股权
美股速递 · 12-15
复星医药称子公司计划投资总额14亿元以收购制药公司控股权
复星医药控股子公司酮洛芬贴剂获准开展III期临床试验
中金财经 · 12-14
复星医药控股子公司酮洛芬贴剂获准开展III期临床试验
复星医药（600196）披露控股子公司药品注册申请获受理，12月12日股价下跌0.91%
证券之星 · 12-12
复星医药（600196）披露控股子公司药品注册申请获受理，12月12日股价下跌0.91%
复星医药 - 获得中国NMPA批准进行其酮洛芬贴剂的临床试验
美股速递 · 12-12
复星医药 - 获得中国NMPA批准进行其酮洛芬贴剂的临床试验
复星医药(600196.SH)：斯鲁利单抗注射液新增适应症药品注册申请获受理
智通财经 · 12-12
复星医药(600196.SH)：斯鲁利单抗注射液新增适应症药品注册申请获受理
复星医药(600196.SH)：酮洛芬贴剂获临床试验批准
智通财经网 · 12-12
复星医药(600196.SH)：酮洛芬贴剂获临床试验批准
复星医药子公司桂林南药膦甲酸钠注射液注册申请获批
财中社 · 12-10
复星医药子公司桂林南药膦甲酸钠注射液注册申请获批
群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元
智通财经 · 12-10
群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.89,"timestamp":1766732401000,"preClose":27.05,"halted":0,"volume":12034818,"delay":0,"changeRate":-0.0059,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"已收盘","change":-0.16,"latestTime":"12-26 15:00:00","open":27,"high":27.09,"low":26.8,"amount":324000000,"amplitude":0.0107,"askPrice":26.9,"askSize":45,"bidPrice":26.89,"bidSize":43,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":27.05,"symbolType":"stock","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":29.76,"lowLimit":24.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.5,"roa":"--","peRate":21.874237,"roe":"5.3%","epsLYR":1.04,"committee":0.641241,"marketValue":71808000000,"turnoverRate":0.0057,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.52,"timestamp":1766549304003,"preClose":20.74,"halted":0,"volume":1216963,"delay":0,"premium":"-31.23"},"floatMarketCap":56966000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2593768604","title":"复星医药：募投项目结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2593768604","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593768604?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:05","pubTimestamp":1766570739,"startTime":"0","endTime":"0","summary":"南财智讯12月24日电，复星医药公告，截至2025年12月22日，公司2022年非公开发行募集资金已全部按承诺投入相关募投项目，专户中的募集资金（包括利息收入）已全部使用完毕，本次发行涉及的募投项目结项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600840925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","600196","BK0239","BK0187","BK0012","BK0060","BK0188","BK1191","BK0096","BK0183","02196","BK1515","BK0175","BK0028","BK1593"],"gpt_icon":0},{"id":"2593413090","title":"复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413090","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413090?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:08","pubTimestamp":1766498900,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，复星医药在互动平台回答投资者提问时表示，公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块，其中药品、器械及诊断产品的主要市场包括中国、美国、欧洲及新兴市场在内的多个国家和地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599787764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","BK0183","BK1515","BK1191","600196","BK0196","159883","BK0239","09996","BK0028","XLV","159760","XBI","BK1222","BK0187","BK1583","BK1100","BK1593","BK0175","BK4585","BK0060","BK0012","BK1574","01477","BK4588","BK4581","BK0188","02196","BK0096","09997"],"gpt_icon":0},{"id":"2592577131","title":"复星医药：控股子公司药品获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592577131","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592577131?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:20","pubTimestamp":1766136033,"startTime":"0","endTime":"0","summary":"南方财经12月19日电，复星医药(600196.SH)公告称，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司获美国FDA批准开展HLX18（重组抗PD-1人源化单克隆抗体注射液）用于治疗多种实体瘤的I期临床试验。复宏汉霖拟于条件具备后于美国开展该药品的I期临床试验。HLX18是复星医药自主研发的纳武利尤单抗生物类似药，拟用于多种癌症的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596838564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0096","BK0239","BK0060","BK0183","BK0175","BK0012","600196","BK1593","BK0187","02196","BK0028","BK1515","BK1191","BK0196"],"gpt_icon":0},{"id":"2592906229","title":"官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906229","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592906229?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:55","pubTimestamp":1766062500,"startTime":"0","endTime":"0","summary":" 多天前，首版《商业健康保险创新药品目录》公布，目录中19种创新药被正式推向了商业健康保险的舞台中央。业内正翘首以待，谁会将目录中的创新药纳入保险保障，成为第一批“吃螃蟹”的保险机构。一则“官宣！复星联合健康保险9款医疗险覆盖商保创新药！”复星联合健康保险的官宣无疑令业内欣喜。 复星联合健康保险“悔棋”动作的背后，与首次推出的《商业健康保险创新药品目录》不无关联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfrcf8430514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0107464264.USD","IE00BJJMRX11.SGD","LU1989771016.USD","LU1084165304.USD","IE00B19Z3B42.SGD","LU1814569148.SGD","LU0861579265.USD","LU0289739699.SGD","LU0011850046.USD","LU0320765059.SGD","IE00BWXC8680.SGD","SG9999014914.USD","IE0004445239.USD","IE00BSNM7G36.USD","LU0203347892.USD","IE00BKPKM429.USD","LU1506573853.SGD","LU1267930490.SGD","LU2236285917.USD","LU0354030438.USD","LU0211326839.USD","LU2357305700.SGD","IE00B1BXHZ80.USD","LU1153585028.USD","LU1934455194.USD","LU0820561818.USD","LU1720051108.HKD","LU1003077747.HKD","LU0353189680.USD","LU1267930573.SGD","IE00BKVL7J92.USD","SG9999017495.SGD","IE00B19Z8X17.USD","LU0198837287.USD","IE00B775H168.HKD","LU0234572021.USD","LU0545039389.USD","BK4585","LU1988902786.USD","SGXZ81514606.USD","LU2264538146.SGD","BK4533","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1035773651.USD","LU2125154778.USD","LU1066053197.SGD","SG9999013999.USD","SG9999018857.SGD","LU2279689827.SGD","LU0345770308.USD","IE0002141913.USD","IE0002270589.USD","LU0965508806.USD","LU1023059063.AUD","LU2111349929.HKD","LU0053666078.USD","LU0354030511.USD","LU0149725797.USD","IE00B4R5TH58.HKD","LU0965509010.AUD","LU1934455863.HKD","LU1983299246.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","02196","LU0238689110.USD","LU1934455277.USD","LU2112291526.USD","LU1037948541.HKD","LU0456855351.SGD","IE00BN29S564.USD","LU0795875086.SGD","LU1066051811.HKD","SG9999014906.USD","LU0029864427.USD","LU0158827781.USD","LU0251132253.USD","LU2324357040.USD","LU0432979614.USD","LU0094547139.USD","LU1061106388.HKD","BK1161","LU1551013342.USD","LU1551013425.SGD","LU2491050154.USD","LU0912757837.SGD","SG9999002224.SGD","LU0052756011.USD","BK1574","LU2468319806.SGD","LU1066051498.USD","LU0128525689.USD","LU2361044865.SGD","IE0005OL40V9.USD","IE00B19Z9Z06.USD","LU0965509283.SGD","LU2125154935.USD","LU0553294199.USD","LU1670628061.USD","LU1674673428.USD","SGXZ57979304.SGD","LU1323610961.USD","IE00BJJMRY28.SGD","LU0557290698.USD","IE00BFXG1179.USD","LU2089284900.SGD","BK4588","LU0114720955.EUR","IE00B19Z9P08.USD","LU2211815571.USD","LU0048584097.USD","IE00BJJMRZ35.SGD","LU2362541513.USD","IE00B19Z8W00.USD","LU0256863811.USD","LU2347655156.SGD","LU2361044949.HKD","SG9999014898.SGD","IE00BZ9MQY76.HKD","LU0187121727.USD","LU2089283258.USD","IE0009355771.USD","IE00B19Z9505.USD","IE00B4JS1V06.HKD","LU0528227936.USD","LU2271345857.HKD","LU0345770993.USD","IE0004445015.USD","LU1670627923.USD","LU0109391861.USD","LU0683600562.USD","LU1066051225.USD","SG9999001176.USD","LU2028103732.USD","LU1064131342.USD","LU1037948897.HKD","LU1119994496.HKD","LU0077335932.USD","SG9999018865.SGD","LU1732799900.SGD","IE00BZ1G4Q59.USD","BK4534","IE00B1XK9C88.USD","IE00B2B36J28.USD","LU0097036916.USD","LU2362541273.HKD","LU2552382058.USD","BK4566","IE00B19Z3581.USD","LU2089984988.USD","BK4532","LU1069347547.HKD","LU1854104046.USD","LU1496350502.SGD","LU0417517546.SGD","LU1267930730.SGD","SG9999001176.SGD","LU0496365809.HKD","LU2461242641.AUD","LU0316494557.USD","LU0708994859.HKD","BK4154","LU1261432733.SGD","LU1778281490.HKD","IE00B7SZLL34.SGD","LU1291159041.SGD","LU0949170772.SGD","LU1674673691.USD","LU0310800965.SGD","LU2552382215.SGD","LU0211327993.USD","LU0128525929.USD","LU0820561909.HKD","LU0738911758.USD","LU2242649171.HKD","LU0672654240.SGD","LU2023251221.USD","LU0976567544.SGD","IE00B7KXQ091.USD","LU0266013472.USD","600196","LU2360032135.SGD","IE000M9KFDE8.USD","LU0661504455.SGD","LU1914381329.SGD","IE00B894F039.SGD","LU0310799852.SGD","LU0787776722.HKD","LU2552382132.HKD","LU0342679015.USD","IE00BFSS7M15.SGD","LU0820562030.AUD","LU2491050071.SGD","LU0689472784.USD","LU0882574055.USD","IE00BFSS8Q28.SGD","LU1854103824.USD","IE00BJT1NW94.SGD","LU2087625088.SGD","LU2244417387.USD","LU1791710400.SGD","LU1791710582.SGD","LU1720051017.SGD","LU0965509101.SGD","LU1548497426.USD","LU2491049909.HKD","LU1732800096.USD","LU0353189763.USD","LU0079474960.USD","SGXZ99366536.SGD","LU2361045086.USD","LU1074936037.SGD","SG9999014880.SGD","LU0211326755.USD","LU0122379950.USD","LU1718418525.SGD","LU0203345920.USD","LU0943347566.SGD","SG9999002232.USD","LU1057294990.SGD","LU0823416689.USD","LU2362540622.SGD","LU0211328371.USD","LU1267930227.SGD","LU0795875169.SGD","BK4581","LU2133065610.SGD","LU0158827948.USD","LU0310800379.SGD","LU0708995401.HKD"],"gpt_icon":0},{"id":"1124569521","title":"复星医药旗下公司与Clavis Bio签署共同开发及独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1124569521","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124569521?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:34","pubTimestamp":1766054051,"startTime":"0","endTime":"0","summary":"复星医药旗下公司与Clavis Bio签署了共同开发及独家许可选项的协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK0060","BK0096","600196","BK0183","BK0028","BK0187","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2592972970","title":"复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972970","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592972970?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:29","pubTimestamp":1766053787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点并推进针对获选靶点化合物的临床前开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0012","600196","BK1191","BK0060","02196","BK0028","BK0175","BK0183","BK1515","BK0196","BK0188","BK1593","BK0096","BK0187"],"gpt_icon":0},{"id":"2592419995","title":"12月17日复星医药现784.3万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2592419995","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592419995?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:50","pubTimestamp":1765965010,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日复星医药发生大宗交易，交易数据如下：大宗交易成交价格25.3元，相对当日收盘价折价5.84%，成交31万股，成交金额784.3万元，买方营业部为民生证券股份有限公司北京第一分公司，卖方营业部为中泰证券股份有限公司杭州湖墅南路证券营业部。近三个月该股共发生2笔大宗交易，合计成交9100.0手，折价成交1笔。截至2025年12月17日收盘，复星医药报收于26.87元，上涨0.45%，换手率0.69%，成交量14.57万手，成交额3.89亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","600196","BK1593","BK0012","BK0096","BK0175","BK0196","BK0028","BK0060","BK1515","BK0187","BK1191","02196","BK0188"],"gpt_icon":0},{"id":"2591988977","title":"甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2591988977","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591988977?lang=zh_cn&edition=full","pubTime":"2025-12-16 17:52","pubTimestamp":1765878774,"startTime":"0","endTime":"0","summary":"12月15日，复星医药宣布，控股子公司复星医药产业与绿谷（上海）医药科技有限公司（“绿谷医药”）及其现有相关股东共同签订相关投资协议，拟出资约14.12亿元控股收购绿谷医药。本次收购完成后，绿谷医药将成为复星医药控股子公司，其核心药品甘露特钠胶囊也将纳入复星医药创新药品管线，主要用于治疗轻度至中度阿尔茨海默病（AD）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163593128594.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593128594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK1515","BK1191","600196","159938","BK1161","BK0196","BK0239","BK0028","BK0187","BK1593","BK0175","BK0060","BK0012","BK1574","09939","BK0188","02196","BK0096"],"gpt_icon":0},{"id":"2591607815","title":"复星医药收购绿谷医药，阿尔兹海默病患者看到曙光？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591607815","media":"读懂财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591607815?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:49","pubTimestamp":1765874940,"startTime":"0","endTime":"0","summary":" “阿尔茨海默病药物研发的“死亡谷”里，一款曾被誉为国产创新药希望、又深陷科学争议的明星药物，正在等待它的救赎。” 12月15日，复星医药宣布收购绿谷医药，其核心产品甘露特钠胶囊也将纳入复星医药创新药品管线。凭借着深厚的全球研发能力和中枢神经领域日益完善的创新药械矩阵，复星医药能否让这款命运多舛的药物重获新生，从而破解现有阿尔茨海默病治疗药物疗效欠佳的困局，成为行业关注的焦点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2025-12-16/doc-inhaysim8510706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02196","09939","BK0239","BK0188","BK0187","BK1593","BK0175","BK0012","BK0028","BK0183","BK1191","600196","BK1515","BK1161","159938","BK0196","BK0060","BK0096"],"gpt_icon":0},{"id":"2591642540","title":"复星医药14亿入局阿尔茨海默病 缘何选择押注绿谷“九期一”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642540","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642540?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:14","pubTimestamp":1765808084,"startTime":"0","endTime":"0","summary":"近日，阿尔茨海默病药物赛道异常热闹。在两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选我国首版《商业健康保险创新药品目录》后，争议与机遇并存的国产阿尔茨海默病药物甘露特钠，在面临停产、换证危机之际，迎来了中国医药巨头复星医药的入局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153592045515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592045515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0096","02196","BK0060","BK0188","BK0187","BK1515","BK1191","BK0196","BK1593","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2591648625","title":"争议药物\"九期一\"获新生？复星医药14亿元收购绿谷医药重启临床与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648625","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648625?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:51","pubTimestamp":1765795877,"startTime":"0","endTime":"0","summary":"此次收购案后，复星医药方面表示，甘露特钠胶囊重新开展商业化生产和销售前，还需补充完成目前尚在开展的上市后确证性临床试验并获得国家药品审评部门批准。本次收购完成后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期尽快实现获批；并适时开展相关适应症的国际多中心临床试验，惠及更多阿尔茨海默病患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765795546434638047","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["600196","BK1593","BK1161","BK1515","BK0239","BK1574","BK0028","BK0187","159938","BK0012","BK0060","BK0096","02196","BK1191","BK0183","BK0175","BK0188","09939","BK0196"],"gpt_icon":1},{"id":"2591612068","title":"复星医药：控股子公司拟出资14.12亿元投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612068","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612068?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791813,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月15日，复星医药(600196.SH)公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591807093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591807093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0187","BK0096","BK1161","BK1191","BK0196","BK0012","159938","BK0060","BK0175","BK1593","BK1515","BK0188","BK1574","BK0183","02196","09939","600196","BK0028"],"gpt_icon":0},{"id":"1126780397","title":"复星医药称子公司计划投资总额14亿元以收购制药公司控股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1126780397","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126780397?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:39","pubTimestamp":1765791549,"startTime":"0","endTime":"0","summary":"复星医药称子公司计划投资总额14亿元以收购制药公司控股权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0187","BK0196","BK0028","BK0183","BK0188","BK0060","BK0012","BK0096","600196","BK0239"],"gpt_icon":0},{"id":"2591865967","title":"复星医药控股子公司酮洛芬贴剂获准开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865967","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865967?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:13","pubTimestamp":1765671185,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月12日发布公告，其控股子公司上海朝晖药业有限公司研发的酮洛芬贴剂，已获得国家药品监督管理局批准，将在中国境内开展III期临床试验。 该事件的影响范围主要集中于复星医药集团及其控股子公司朝晖药业的研发管线推进，以及未来潜在的非甾体抗炎药外用贴剂市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0187","02196","BK0096","BK0012","BK0060","BK0175","BK4134","III","600196","BK0188","BK1593","BK0183","BK0196","BK1515","BK0028","BK1191","BK0239"],"gpt_icon":0},{"id":"2590504257","title":"复星医药（600196）披露控股子公司药品注册申请获受理，12月12日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504257","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504257?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:07","pubTimestamp":1765548445,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，复星医药报收于28.28元，较前一交易日下跌0.91%，最新总市值为755.2亿元。该股当日开盘28.5元，最高28.59元，最低28.01元，成交额达5.67亿元，换手率为0.95%。近日，上海复星医药（集团）股份有限公司发布公告称，其控股子公司复宏汉霖就斯鲁利单抗注射液新增适应症的药品注册申请获国家药监局受理，并纳入优先审评程序。本次注册申请获受理不会对本集团现阶段业绩产生重大影响，后续仍需获得药品注册批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0183","BK1593","BK0175","BK0060","BK0188","BK0012","BK0196","BK0096","02196","BK1191","BK0239","BK0187","600196","BK0028"],"gpt_icon":0},{"id":"1131912390","title":"复星医药 - 获得中国NMPA批准进行其酮洛芬贴剂的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1131912390","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131912390?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:37","pubTimestamp":1765539432,"startTime":"0","endTime":"0","summary":"复星医药 - 获得中国NMPA批准进行其酮洛芬贴剂的临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0096","BK0060","BK0188","BK0187","BK0196","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2590572449","title":"复星医药(600196.SH)：斯鲁利单抗注射液新增适应症药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590572449","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590572449?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:38","pubTimestamp":1765532312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司就斯鲁利单抗注射液新增适应症的药品注册申请获国家药品监督管理局受理，并已获纳入优先审评程序。该药品为集团自主研发的创新型抗PD-1单抗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1191","BK0028","600196","02196","BK0183","BK1515","BK0175","BK1593","BK0012","BK0239","BK0187","BK0096","BK0188","BK0060"],"gpt_icon":0},{"id":"2590506572","title":"复星医药(600196.SH)：酮洛芬贴剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506572","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590506572?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:32","pubTimestamp":1765531926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海朝晖药业有限公司(以下简称“朝晖药业”)收到国家药品监督管理局(以下简称“国家药监局”)关于同意酮洛芬贴剂(以下简称“该药品”)开展临床试验的批准。朝晖药业拟于条件具备后于中国境内1开展该药品的Ⅲ期临床试验。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600196","BK0060","BK1191","BK0028","BK0012","BK0188","BK0196","BK1593","BK0187","02196","BK0175","BK0239","BK0096","BK0183","BK1515"],"gpt_icon":0},{"id":"2590307040","title":"复星医药子公司桂林南药膦甲酸钠注射液注册申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2590307040","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590307040?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:55","pubTimestamp":1765356926,"startTime":"0","endTime":"0","summary":"12月10日，复星医药（600196/02196）发布公告，控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请已获国家药品监督管理局批准。该药品适应症包括用于治疗艾滋病患者巨细胞病毒性视网膜炎和免疫功能损害患者耐阿昔洛韦单纯疱疹病毒性皮肤粘膜感染。截至2025年11月，公司针对该药品的研发累计投入约为498万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587726156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0188","BK1191","BK0060","BK1593","BK0096","02196","600196","BK0183","BK0028","BK0187","BK1515","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2590309455","title":"群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309455","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309455?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:24","pubTimestamp":1765351440,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，群益证券发布研报称，为反映复星医药大额首付款增厚利润，该行上调盈利预测。该行预计公司2025-2027年分别实现净利润33.2亿元、46.8亿元、47.7亿元，YOY分别+19.8%、+40.8%、+19.1%，EPS分别为1.2元、1.8元、1.8元，对应H股PE分别为16X/11X/11X,H股估值偏低，该行看好其长期发展，维持H股“买进”的投资评级，目标价26.5港元。此外，基于许可产品的年度净销售额达成情况，由辉瑞向药友制药支付至多15.85亿美元的销售里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","600196","161027"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766832721486,"stockEarnings":[{"period":"1week","weight":-0.0139},{"period":"1month","weight":-0.0232},{"period":"3month","weight":-0.081},{"period":"6month","weight":0.0995},{"period":"1year","weight":0.0786},{"period":"ytd","weight":0.0946}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}